Also found in: Medical.
HER4Human Epidermal Growth Factor Receptor 4
References in periodicals archive ?
34) A more recent study (35) found distinct expression of HER family molecules, especially EGFR and HER4, which may provide predictive outcome information in patients with ameloblastomas.
Neratinib is an oral, irreversible inhibitor of HER1, HER2 and HER4.
HER2/neu (ErbB2) is a member of the human epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases including EGFR (HER1, ErbB1), HER2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4).
In addition, however, HER2 is also a favoured heterodimer partner for HER1, HER3 or HER4.
Three of these ERBB family blockers under investigation are afatinib (BIBW2992; Boehringer Ingelheim, Ingelheim, Germany), (54,56) dacomitinib, (57) and XL647, (58) Afatinib irreversibly binds to HER2/neu, HER4, and EGFR, even when the most common acquired resistance mutation (T790M) is present.
HER2 is part of a super-family of tyrosine kinase receptors which includes HER1, HER3 and HER4.
Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4.
It belongs to a family of four transmembrane tyrosine kinase cell surface receptors which also includes HER1, HER3 and HER4.